(Q38264378)

1 September 2017

title

Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy (English)

1 reference

1 September 2017

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Giuseppe Cicero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Christian Rolfo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

7

Viviana Bazan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Giuseppe Bronte

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Francesca Lo Vullo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Gianfranco Pernice

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Eugenio Fiorentino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Antonio Russo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

3 November 2014

1 reference

Expert Opinion on Investigational Drugs

1 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

125-132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

Cancer incidence and mortality in Europe, 2004

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Farletuzumab in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Targeted therapies in development for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Morphogenics as a tool for target discovery and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Farletuzumab in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2015.979284

10.1517/13543784.2015.979284

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25363562%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference